China Traditional Chinese Medicine Holdings Co (HKSE:00570) 3-Year EBITDA Growth Rate : -9.30% (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is China Traditional Chinese Medicine Holdings Co 3-Year EBITDA Growth Rate?

China Traditional Chinese Medicine Holdings Co's EBITDA per Share for the six months ended in Dec. 2023 was HK$0.13.

During the past 12 months, China Traditional Chinese Medicine Holdings Co's average EBITDA Per Share Growth Rate was 15.90% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -9.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -4.10% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 10.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of China Traditional Chinese Medicine Holdings Co was 55.10% per year. The lowest was -42.10% per year. And the median was 9.85% per year.

Competitive Comparison of China Traditional Chinese Medicine Holdings Co's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, China Traditional Chinese Medicine Holdings Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Traditional Chinese Medicine Holdings Co's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Traditional Chinese Medicine Holdings Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where China Traditional Chinese Medicine Holdings Co's 3-Year EBITDA Growth Rate falls into.

China Traditional Chinese Medicine Holdings Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

China Traditional Chinese Medicine Holdings Co (HKSE:00570) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

China Traditional Chinese Medicine Holdings Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of China Traditional Chinese Medicine Holdings Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

China Traditional Chinese Medicine Holdings Co (HKSE:00570) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Traditional Chinese Medicine Holdings Co Ltd (HKSE:00570) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

WSG:Germany

Address

288 Hennessy Road, Room 1601, Emperor Group Centre, Wanchai, Hong Kong, HKG

Website

https://www.china-tcm.com.cn

China Traditional Chinese Medicine Holdings Co Ltd is engaged in the Chinese healthcare sector. The company functions through five segments, finished drugs; concentrated TCM granules; TCM decoction pieces; TCM healthcare complex, and Local TCM integrated operation. It generates maximum revenue from the concentrated TCM granules segment. Geographically, it derives a majority of its revenue from Mainland China.

China Traditional Chinese Medicine Holdings Co (HKSE:00570) Headlines

No Headlines